Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Paris - Delayed Quote EUR

MaaT Pharma SA (MAAT.PA)

Compare
6.04
-0.14
(-2.27%)
At close: April 17 at 5:35:07 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MAAT.PA

Recent News: MAAT.PA

View More
Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)

Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)
Business Wire 4 days ago
MaaT Pharma reports safety interim analysis from trial of microbiome therapy

MaaT Pharma reports safety interim analysis from trial of microbiome therapy
Clinical Trials Arena 9 days ago
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
Business Wire 10 days ago
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co

MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co
Business Wire 11 days ago
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Business Wire 14 days ago
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
Business Wire 18 days ago
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results

MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results
Business Wire 22 days ago
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease
Business Wire last month
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013

MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013
Business Wire last month
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
Business Wire 2 months ago
Maat Pharma Phase III microbiome trial hits endpoints as stock soars

Maat Pharma Phase III microbiome trial hits endpoints as stock soars
Clinical Trials Arena 3 months ago
View More

Related Tickers

RFM.F Sensorion SA
0.1900
-26.92%
 
PHGE BiomX Inc.
0.5397
-0.11%
 
PRTC.L PureTech Health plc
123.40
+0.82%
 
IDIA.SW Idorsia Ltd
1.1400
+1.42%
 
KALV KalVista Pharmaceuticals, Inc.
12.00
+2.17%
 
MRUS Merus N.V.
43.06
+2.73%
 
MCRB Seres Therapeutics, Inc.
0.3700
-7.48%
 
DAWN Day One Biopharmaceuticals, Inc.
6.84
+1.18%
 
PHAT Phathom Pharmaceuticals, Inc.
4.0300
-4.62%
 
SWTX SpringWorks Therapeutics, Inc.
37.92
+0.48%